Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.60 |
| ▸ | NPY4R | P50391 | 4/20 | 0.58 |
| ▸ | NPY1R | P25929 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131648 | 1.00 | OPRK1 (0.60) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL29612429 | 0.95 | NPY4R (0.60) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL3649802 | 0.95 | NPY4R (0.67) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL3649800 | 0.95 | NPY4R (0.67) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL29568486 | 0.92 | OPRM1 (0.57) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL31343356 | 0.92 | OPRK1 (0.60) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL29679986 | 0.92 | NPY4R (0.62) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL30957130 | 0.92 | OPRK1 (0.69) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL30957133 | 0.92 | OPRK1 (0.69) | OPRK1NPY4RNPY1RNPY2ROPRM1 | |
| SCHEMBL30957126 | 0.92 | OPRK1 (0.69) | OPRK1NPY4RNPY1RNPY2ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050100507-A1 | Chemotactic peptide antagonists for imaging sites of inflammation | BRACCO IMAGING S.P.A. (IT) | 2005-05-12 | — | — | US | disclosed |
| US-6872536-B1 | Chemotactic peptide antagonists for imaging sites of inflammation | BRACCO IMAGING S.P.A. (IT) | 2005-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050100507-A1 | Chemotactic peptide antagonists for imaging sites of inflammation | FPR3, FPR1, FPR2 | OPRK1 507/4885NPY4R 546/4885NPY1R 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.